Method and kit for making an in vitro prognosis of severity for a patient in septic shock

A method of measuring gene expression for a patient in septic shock, comprising:

• obtaining a biological sample taken from the patient in septic shock within 12 hours from onset of septic shock, which is characterized at least by sepsis, dysfunction of at least one organ, and hypotension despite volume-expander treatment;
• and
• assaying the biological sample to measure an expression level of an expression product expressed from any of (i) a Homo sapiens leukocyte immunoglobulin-like receptor, subfamily B with transmembrane domain (TM) and immunoreceptor tyrosine-based inhibition motif (ITIM) domains, member 2 (lilrb2) gene, or (ii) a Homo sapiens leukocyte immunoglobulin-like receptor, subfamily B with TM and ITIM domains, member 1 (lilrb1) gene,
• wherein the expression level of the expression product is measured without hybridization on a biochip.

A method of measuring gene expression for a patient in septic shock, comprising:

• obtaining a biological sample taken from the patient in septic shock;
• and
• assaying the biological sample to measure whether there is overexpression relative to a control level from either a healthy subject or non-surviving septic-shock patient of an expression product expressed from any of (i) a Homo sapiens leukocyte immunoglobulin-like receptor, subfamily B with transmembrane domain (TM) and immunoreceptor tyrosine-based inhibition motif (ITIM) domains, member 2 (lilrb2) gene, or (ii) a Homo sapiens leukocyte immunoglobulin-like receptor, subfamily B with TM and ITIM domains, member 1 (lilrb1) gene,
• wherein an expression level of the expression product is measured without hybridization on a biochip.